Showing 991-1000 of 9426 results for "".
SDPA: Dr. Matthew Zirwas Shares Passion for Treating Atopic Dermatitis
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-shares-passion-for-treating-atopic-dermatitis/29509/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. He provides a passionate overview of his lecture on atopic dermatitis, itch, and contact dermatitis.SDPA: Dr. Audrey Rutherford Shares How Vulvovaginal Dermatology Became Her Specialty
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-audrey-rutherford-shares-how-vulvovaginal-dermatology-became-her-specialty/29511/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Audrey Rutherford, MD. Dr. Rutherford shares how she got started in vulvovaginal dermatology and key takeaways from her lecture.SDPA: Andrew Mastro on Advancing Career By Building Yearly Goals
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-andrew-mastro-on-advancing-career-by-building-yearly-goals/29512/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Andrew Mastro, PA-C. Each year, Mastro leaves SDPA with a yearly goal in mind. He breaks down how SDPA contributes to the goal and what he does to achieve it.Verrucous Psoriasis: A Rare Variant Refractory to Topical Steroids
https://practicaldermatology.com/topics/psoriasis/verrucous-psoriasis-a-rare-variant-refractory-to-topical-steroids/29204/In this case study, researchers present a patient with VP of the dorsal fingers that was initially diagnosed as psoriasis and treated with multiple topical steroids. Ultimately, the patient was refractory to steroid topical therapy and required consideration of alternative treatments for definitiveDermWire TV Extra: Dr. Swanson on BPO
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-dr-swanson-bpo/29166/Practical Dermatology Editorial Board member Elizabeth (Lisa) Swanson, MD, FAAD, addresses the recent news involving the safety of benzoyl peroxide products.Dr. Ross on Therapeutic and Warning Endpoints for Laser Therapy in Skin of Color Patients
https://practicaldermatology.com/topics/skin-of-color/dr-ross-on-therapeutic-and-warning-endpoints-for-laser-therapy-in-skin-of-color-patients/28657/E. Victor Ross, MD, discusses his presentations at the Skin of Color Update, where he addressed ways to enhance using laser therapy in practice on patients with skin of color.Technology Solutions: Q&A With Nextech's Dr. Jason Handza
https://practicaldermatology.com/topics/practice-management/technology-solutions-q-nextechs-dr-jason-handza/28649/Nextech this year introduced Nextech RCM Professional Billing Services, an addition to their practice management software suite. This solution simplifies insurance billing complexities, helping practices reduce administrative burdens and enhance financial performance through optimized cash flow.Sensus Healthcare: What's Next
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-next/19947/Along with other healthcare companies, Sensus faced challenges in 2020 as the COVID-19 pandemic emerged. But CEO Joe Sardano says the company is poised for success in 2021 and beyond. He discusses efforts to optimize physician reimbursement and strategies to expand access for patients.Sensus Healthcare: What's New
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-new/19946/Adding to its flagship SRT-100 device for superficial radiation therapy, Sensus has launched the Sculptura® Radiotherapy Oncology System and is poised to bring new aesthetic devices to market. Sensus CEO Joe Sardano says that as it grows, the company remains focused on relationships with its clientsAlmost There: Toward Systemic Therapy for AD in Children
https://practicaldermatology.com/topics/atopic-dermatitis/almost-there-toward-systemic-therapy-for-ad-in-children/19934/With the approval of the first biologic for management of atopic dermatitis, a new era is underway, says Amy Paller, MD. She addresses the role of dupilumab in practice and provides a look ahead at other agents in the pipeline for adolescent and pediatric patients.